Tests a skin drug, ruxolitinib, alone or with an eczema action plan
Tests ruxolitinib with or without an action plan in people with atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Opzelura Experience Study
Key facts
- Where
- Winston-Salem, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT07661979
- Record updated
- 4 September 2026
- Original description
Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.Read full original descriptionShow less
Opzelura Experience Study
Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.
Inclusion: Patients ≥2 years of age; Patients with a current diagnosis of atopic dermatitis that is mild-to-moderate in severity and in ≥2 body areas; Patients with up to 20% total body surface area involvement; Women of childbearing age taking/using a contraceptive.
Exclusion: Patients who are prescribed changing systemic medications or treatments (phototherapy, biologics) for atopic dermatitis; Patients who would require use of other topical medications for other diagnoses (tretinoin, clindamycin); Patients with areas of skin with active infection; Patients without a current diagnosis of atopic dermatitis; Patients who are pregnant.